A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
Status:
Active, not recruiting
Trial end date:
2022-06-19
Target enrollment:
Participant gender:
Summary
The reason for this study is to see how effective and safe the study drug known as
baricitinib is in participants with systemic lupus erythematosus (SLE).